Market Overview

UPDATE: Burrill Initiates Rexahn Pharmaceuticals at Market Outperform on Promising Oncology Drug

Related RNN
Events for the Week of Nov. 17-21, 2014
Rexahn Receives A Notice of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform

Burrill initiated coverage on Rexahn Pharmaceuticals (NYSE: RNN) with a Market Outperform rating and a $1 price target.

Burrill commented, "We believe that Rexahn's promising pipeline in oncology and CNS disorders is undervalued, and a successful result in any of the ongoing trials may offer significant upside for investors with high risk tolerance. … Rexahn's leading oncology drug, Archexin, is a first-in-class anti-sense drug targeting the Akt-1 gene, with an orphan designation for glioblastoma, pancreatic, stomach, ovarian, and renal cancers. Rexahn has completed a Phase 2a trial in pancreatic cancer, with promising survival data in a subset of evaluable patients."

Rexahn Pharmaceuticals closed at $0.29 on Thursday.

Latest Ratings for RNN

Sep 2014Laidlaw & Co.Initiates Coverage onBuy
Mar 2014Brinson PatrickInitiates Coverage onOutperform
Jan 2014Roth CapitalInitiates Coverage onBuy

View More Analyst Ratings for RNN
View the Latest Analyst Ratings

Posted-In: BurrillAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (RNN)

Around the Web, We're Loving...

Get Benzinga's Newsletters